ReviewNeural plasticity2012
Induced pluripotent stem cells to model and treat neurogenetic disorders.
Review in Neural plasticity, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Genetic investigation of the ubiquitin-protein ligase E3A gene as putative target in Angelman syndrome.World journal of clinical cases · 2024Article
- Application of iPSC to Modelling of Respiratory Diseases.Advances in experimental medicine and biology · 2020Review
- Modeling Neurological Diseases With Human Brain Organoids.Frontiers in synaptic neuroscience · 2018Review
- Functional Deficiencies in Fragile X Neurons Derived from Human Embryonic Stem Cells.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015Article
- Review
- Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes.Frontiers in cellular neuroscience · 2015Review
- Autism spectrum disorders: emerging mechanisms and mechanism-based treatment.Frontiers in cellular neuroscience · 2015Article
- Stem cell therapy: a look at current research, regulations, and remaining hurdles.P & T : a peer-reviewed journal for formulary management · 2014Article
- Amyotrophic lateral sclerosis - cell based therapy and novel therapeutic development.Experimental neurobiology · 2014Review
- A multiplex high-throughput gene expression assay to simultaneously detect disease and functional markers in induced pluripotent stem cell-derived retinal pigment epithelium.Stem cells translational medicine · 2014Article
- Modeling neurodevelopmental disorders using human pluripotent stem cells.Stem cell reviews and reports · 2014Review
- Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application.Blood research · 2014Review
- Neural stem cells: are they the hope of a better life for patients with fetal-onset hydrocephalus?Fluids and barriers of the CNS · 2014Review
- Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells.Acta pharmacologica Sinica · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remarkable advances in cellular reprogramming have made it possible to generate pluripotent stem cells from somatic cells, such as fibroblasts obtained from human skin biopsies. As a result, human diseases can now be investigated in relevant cell populations derived from induced pluripotent stem cells (iPSCs) of patients. The rapid growth of iPSC technology has turned these cells into multipurpose basic and clinical research tools. In this paper, we highlight the roles of iPSC technology that are helping us to understand and potentially treat neurological diseases. Recent studies using iPSCs to model various neurogenetic disorders are summarized, and we discuss the therapeutic implications of iPSCs, including drug screening and cell therapy for neurogenetic disorders. Although iPSCs have been used in animal models with promising results to treat neurogenetic disorders, there are still many issues associated with reprogramming that must be addressed before iPSC technology can be fully exploited with translation to the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.